NCT07216703 2026-04-17
TroFuse-036
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
27 trialsNCT07418749 2026-04-06
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT03635567 2026-02-04
KEYNOTE-826
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00980954 2025-12-31
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04982237 2025-11-19
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Akeso
Phase 3 Active not recruiting
NCT02446652 2025-05-29
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
National Institute of Cancerología
Phase 3 Withdrawn
NCT05179239 2025-04-15
A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Terminated
NCT06870565 2025-03-17
Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma
Women's Hospital School Of Medicine Zhejiang University
Phase 3 Not yet recruiting
NCT03556839 2025-01-08
BEATcc
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Active not recruiting
NCT01566240 2024-12-05
INTERLACE
University College, London
Phase 3 Active not recruiting
NCT04723875 2024-11-01
Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline
Huazhong University of Science and Technology
Phase 3 Active not recruiting
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT03534713 2023-09-21
ONCOCOL01
University Hospital, Toulouse
Phase 3 Recruiting
NCT05446883 2022-11-30
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT01414608 2022-11-07
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
GOG Foundation
Phase 3 Completed
NCT05384366 2022-05-20
Neoadjuvant Chemotherapy in Cervical Cancer
Banaras Hindu University
Phase 3 Completed
NCT04806945 2022-05-05
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT03912415 2020-09-18
FERMATA
Biocad
Phase 3 Unknown
NCT00803062 2019-07-23
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00064077 2018-10-17
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
GOG Foundation
Phase 3 Completed
NCT02629718 2018-03-16
SYSGO-003
Sun Yat-sen University
Phase 3 Unknown
NCT02036164 2017-04-06
ACT-LACC
Navamindradhiraj University
Phase 3 Unknown
NCT02595554 2017-02-03
SYSGO002
Sun Yat-sen University
Phase 3 Unknown
NCT01755845 2016-04-28
Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients
Wenzhou Medical University
Phase 3 Unknown
NCT01756170 2016-04-28
Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients
Wenzhou Medical University
Phase 3 Unknown
NCT02422563 2015-04-21
NACOPRAD
Charite University, Berlin, Germany
Phase 3 Unknown
NCT00057928 2012-06-13
S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer
SWOG Cancer Research Network
Phase 3 Withdrawn